Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 Use and Plastic Surgery Outcomes
Thirteen studies found no clear overall increase in five postoperative complications, but a very-low-certainty scarring signal emerged.
Why we wrote this. Individual retrospective reports can make perioperative risk sound settled. This pooled review shows which outcomes remained inconclusive and why the scarring signal is still hypothesis-generating.
In this article (5 sections)
A 2026 systematic review pooled 13 comparative studies of preoperative GLP-1 receptor agonist use in plastic and reconstructive surgery. Across 17,426 adults, most postoperative complication estimates did not differ significantly between 8,745 users and non-users. Hypertrophic scarring was the exception, with a pooled risk ratio of 1.55 and a 95% confidence interval from 1.01 to 2.38[1]. The authors rated the evidence very low certainty.
The review enrolled 0 new participants and generated 0 original patient outcomes. It synthesized existing comparative studies through May 2026. The paper does not establish that continuing, pausing or restarting semaglutide at a particular time changes surgical risk, and it does not test a medication-withholding protocol[2].
What the researchers pooled
The authors searched PubMed, Embase, Cochrane, ClinicalTrials.gov and the World Health Organization trial registry for adult plastic and reconstructive surgery studies comparing preoperative GLP-1 use with no use. They pooled risk ratios with a random-effects method and prespecified general-population, post-bariatric and reconstructive subgroups[2].
The 13 studies covered several operations and patient groups; there was no single standardized procedure. That breadth is useful for mapping the field, but it weakens a single bedside interpretation. Wound risk after body contouring may not match risk after flap reconstruction, breast surgery or diabetic-foot reconstruction.
The indexed abstract identifies the evidence as Level III risk or prognostic evidence. It does not report randomized allocation. Comparative observational studies can adjust or match measured differences, but patients using GLP-1 medicines may differ from non-users in diabetes, weight history, nutritional status, procedure type and perioperative care.
Five common complications were inconclusive
Wound dehiscence had a pooled risk ratio of 1.05, with a confidence interval from 0.73 to 1.52. Surgical-site infection had a ratio of 0.83, from 0.60 to 1.16. Both intervals included 1. These estimates therefore did not demonstrate either higher or lower overall risk[1].
Seroma had a risk ratio of 1.12 with a 95% confidence interval from 0.67 to 1.87. Hematoma was 1.13, from 0.67 to 1.90. Venous thromboembolism was 0.61, from 0.34 to 1.08[2]. Wide intervals leave room for clinically relevant benefit or harm, so a non-significant result is not evidence that risks are identical.
A pooled relative risk also needs baseline risk. The same ratio can imply different absolute differences after a low-risk operation and a high-risk reconstruction. The abstract does not provide pooled absolute event rates, so those numbers should not be converted into a personalized percentage.
The scarring result is a signal, not a verdict
Hypertrophic scarring was the only outcome with a confidence interval that narrowly excluded 1. The pooled risk ratio was 1.55, but the lower confidence limit was 1.01. That statistical boundary is fragile, particularly within a review that explicitly grades the overall evidence as very low certainty[1].
Observational data cannot isolate a direct drug effect from the reason a medicine was prescribed or from the path of weight loss before surgery. Glycemic control, rapid weight change, prior bariatric surgery, protein intake, smoking and surgical technique can all influence healing. Unless designs measure and balance those factors well, residual confounding remains.
The result also does not show whether a short preoperative pause would change scar biology. Exposure definitions in database studies may describe prescription or recorded use, not actual dosing, duration or the last administration before surgery. A medicine-specific and timing-specific trial would be needed to answer that management question.
Subgroup findings need extra caution
Tests did not identify significant differences among general-population, post-bariatric and reconstructive subgroups for most outcomes. Surgical-site infection was the exception, with a statistically significant subgroup difference and lower rates in the reconstructive subgroup[2]. That is an interaction across groups, not proof that GLP-1 use prevents infection after reconstruction.
Subgroup comparisons are especially vulnerable when few studies contribute to each stratum. Procedure mix, patient selection and outcome definitions may vary at the same time. A lower pooled rate in one category can reflect those differences rather than a medicine effect.
How this changes the earlier safety picture
Earlier narrative reviews highlighted individual retrospective reports of increased wound complications and proposed perioperative concerns. This newer review owns a different question: it pools comparative postoperative outcomes across 13 studies. Its overall estimates do not confirm a broad increase in dehiscence, infection, seroma, hematoma or venous thromboembolism, but certainty remains too low to declare those outcomes unaffected.
Readers should not use the meta-analysis to choose a stop date or change a prescribed medicine independently. Perioperative management depends on procedure, anesthesia plan, indication, symptoms and current guidance. The source itself supports individualized management rather than routine restriction. Broader semaglutide safety information cannot substitute for a surgical assessment.
The most defensible conclusion is modest. A pooled scarring signal deserves prospective study. Five other complication estimates remained inconclusive; they did not show reassuringly identical risk. Better research needs prospective exposure measurement, procedure-specific cohorts, standardized complication definitions and enough events to estimate absolute risk.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Was this a new surgical trial?
No. It was a systematic review and meta-analysis of 13 comparative studies involving 17,426 adults. The review enrolled no new participants.
Did GLP-1 use increase wound complications overall?
The pooled estimates for dehiscence, infection, seroma, hematoma and venous thromboembolism were not statistically significant, but wide intervals and very low certainty prevent a conclusion of equal risk.
Does the review tell patients when to stop semaglutide before surgery?
No. It did not test a medication-withholding schedule. Any perioperative medication decision requires individualized coordination with the prescriber, surgeon and anesthesia team.
Sources
No revisions yet. First published .